BioAffinity Technologies reports accelerating sales growth of CyPath Lung tests

BioAffinity Technologies reported accelerating growth of 375% in CyPath Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath Lung is a noninvasive test to detect early-stage lung cancer. BioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath Lung in preparation for expanding to the national market.